Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease. The 2018 Type 2 Diabetes Unmet Need content focuses on leading branded agents and analysis of more available clinical data. Several currently marketed agents have scope to further move up the treatment algorithm. Therefore, understanding physicians’ perception of these products has become increasingly important. This study reveals which drug attributes drive endocrinologists’ prescribing behavior and explores how current therapies compare across efficacy, safety, and delivery attributes.
Which drugs offer the greatest ability to reduce HbA1c to target?
Which drug attributes are key influencers, which have limited impact, and which represent hidden opportunities?
What price range and clinical attributes of new T2D drugs are needed to influence physicians’ prescribing preference over current market players?
How do the leading diabetes brands compare among endocrinologists, and do opinions vary between U.S. and European physicians?
Unmet Need provides quantitative insight into U.S. and European physicians’ perception of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, and the United Kingdom.
Primary research: Survey of 61 U.S. endocrinologists and 31 European endocrinologists.
Key drugs: Victoza, Trulicity, Invokana, Jardiance, Farxiga/Forxiga, Januvia, and Onglyza.
Key metrics included:
Stated versus derived analysis of U.S. and European physicians’ prescribing behavior.
Conjoint analysis with U.S. and European physicians includes market simulator.
Assessment of current therapies’ performance against treatment drivers and goals.
Physicians’ perception of unmet need in this disease and related indications.
Analysis of remaining drug development opportunities.